Marker Therapeutics
MRKR
49 hedge funds and large institutions have $10.3M invested in Marker Therapeutics in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 19 closing their positions.
1,050% more call options, than puts
Call options by funds: $69K | Put options by funds: $6K
0.38% less ownership
Funds ownership: 3.19% → 2.81% (-0.38%)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
23% less funds holding
Funds holding: 64 → 49 (-15)
59% less capital invested
Capital invested by funds: $25.1M → $10.3M (-$14.9M)
79% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$687K |
| 2 |
AAM
AR Asset Management
West Hollywood,
California
|
+$119K |
| 3 |
Mercer Global Advisors
Denver,
Colorado
|
+$25.7K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$15.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$591K |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$561K |
| 3 |
Norges Bank
Oslo,
Norway
|
-$421K |
| 4 |
Renaissance Technologies
New York
|
-$277K |
| 5 |
Millennium Management
New York
|
-$245K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Dimensional Fund Advisors
Austin,
Texas
| – | -$62K | -6,505 | Closed |
|
52
Goldman Sachs
New York
| – | -$32K | -3,382 | Closed |
|
53
Charles Schwab
San Francisco,
California
| – | -$26K | -2,656 | Closed |
|
|
PPA
54
Parametric Portfolio Associates
Seattle,
Washington
| – | -$24K | -2,554 | Closed |
|
|
BCI
55
Brinker Capital Investments
Berwyn,
Pennsylvania
| – | -$21K | -2,173 | Closed |
|
|
SFI
56
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$18K | -1,925 | Closed |
|
|
ECM
57
ExodusPoint Capital Management
New York
| – | -$18K | -1,878 | Closed |
|
|
VCA
58
Verdence Capital Advisors
Hunt Valley,
Maryland
| – | -$18K | -1,844 | Closed |
|
59
HSBC Holdings
London,
United Kingdom
| – | -$16K | -1,669 | Closed |
|
60
Citadel Advisors
Miami,
Florida
| – | -$9.44K | -1,651 | Closed |
|
|
VF
61
Virtu Financial
New York
| – | -$12K | -1,303 | Closed |
|
|
EGM
62
Engineers Gate Manager
New York
| – | -$11K | -1,194 | Closed |
|
|
EVM
63
Eaton Vance Management
Boston,
Massachusetts
| – | -$8K | -821 | Closed |
|
64
Citigroup
New York
| – | +$400 | +70 | New |
|
MRKR Hedge Fund Activity: Q1 2022 in Review
49 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2022, worth a combined $10.3M — down 59% from $25.1M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of MRKR and 4 opened new positions — a net loss of 15 holders — while 11 trimmed existing stakes and 9 added.
The largest buyer was Long Focus Capital Management, adding an estimated $687K. The largest seller was Victory Capital Management, exiting entirely with an estimated $591K sold.
- 49 institutional investors held Marker Therapeutics (MRKR) as of Q1 2022, down from 64 in Q4 2021.
- Funds reported $10.3M of Marker Therapeutics stock for Q1 2022, down 59% quarter-over-quarter.
- 4 funds opened new Marker Therapeutics positions in Q1 2022 and 19 closed out, a net change of -15 holders.
- The largest Marker Therapeutics buyer in Q1 2022 was Long Focus Capital Management, an estimated $687K added.
- The largest Marker Therapeutics seller in Q1 2022 was Victory Capital Management, an estimated $591K sold.
Based on aggregated 13F filings for Q1 2022.